Media Highlights and Announcements
November 09, 2021
With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.
Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.
November 08, 2021
Crawley-based Artrya has been shortlisted as a preferred supplier of AI Software by the UK Health Service for its heart disease detection program.
November 04, 2021
In this article, the Financial Review shares some information on our accomplishments, IPO and overall progress towards our goals.
After closing our initial public offering (IPO), the Motley Fool shares details on Artrya’s AI technology and how it could disrupt the detection of coronary artery disease for years to come.
October 26, 2021
Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack.
October 25, 2021
Artrya’s co-founder and Managing Director, John Barrington AM, recently took part in a Q&A with Stockhead.
Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange.
September 23, 2021
We’re proud to be acknowledged in Signify Research’s Product Developments & Technology Trends report.